Post-test for Obesity medications: What every dietitian needs to know with Joy Bauer, Beth Czerwony and Colleen Dawkins
Presented by Dietitian Connection on September 12, 2024

CPEU webinar post-test

Privacy Collection Statement

The purpose of this statement is to advise you that we may collect, use and disclose various personal information about you, for the purposes of providing services to you, facilitating our internal business operations, including the fullfilment of any legal and regulatory requirements and providing you with information about us and the services that we offer. More detailed information about the way we use, disclose and secure your personal information, and how you can access that information, can be found in our privacy policy, available on the Dietitian Connection website or by contacting us using our details shown on the website.

Question Title

* 1. Name

Question Title

* 2. Email address

Question Title

* 3. Which of the following medications are commonly used for the treatment of obesity and weight management?

Liraglutide

Semaglutide

Tirzepatide

All of the above

Question Title

* 4. What are the potential side effects of these medications?

Decreased appetite

Nausea and vomiting

Constipation

Diarrhea

All of the above

Question Title

* 5. Check all that apply: What additional nutritional considerations should be taken for those on GLP-1 medications?

Protein recommendations to preserve muscle

Hydration

Specific micronutrient needs

Question Title

* 6. True or false: These medications usually need to be used long term because we are treating a chronic disease

True

False

Question Title

* 7. Is there any feedback you'd like to share about the program?

US dietitians: RDs and DTRs may share information with CDR staff regarding the quality of this or any CDR CPEU Prior Approved Activity by emailing QualityCPE@eatright.org. Click this link to provide additional feedback requested by CDR.

Please click DONE to be re-directed to your evaluation score and CPE certificate